Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDR132L in stable heart failure of ischemic origin
NCT04045405Phase 1Completed
- Sponsor
- Cardior Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Jan 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF) comparing CDR132L with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 4 months. Started Jun 2019; status: completed.
02
Drugs
CDR132L
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04045405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045405.